• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Roche Holding AG Basel American Depositary Shares (OP: RHHBY )

    39.26 +0.45 (+1.16%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Roche Holding AG Basel American Depositary Shares

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    27 28 Next >
    New England Journal of Medicine Publishes Landmark Phase III Results for Genentech’s Itovebi, Showing More Than Doubling of Progression-Free Survival in Certain Type of HR-Positive Advanced Breast Cancer
    From Genentech
    Via Business Wire
    Why Alphabet Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Biotech Momentum Trades For The Q4 Rally
    The biotech sector made an interim peak in late February followed by an active summer in very choppy trading. 
    Via Talk Markets
    Stock Market Mixed But Nasdaq Hits Record High As Tesla Leads Earnings Winners: Weekly Review
    The major indexes were mixed for the week. 
    Via Investor's Business Daily
    Roche's Q3 Sales Surge Led By Ocrevus, Vabysmo, Urges Regulators To Block Novo Holdings' $16.5B Catalent Acquisition
    Roche reported a 9% increase in third-quarter sales, driven by strong performance from Ocrevus and Vabysmo. Roche also raised concerns over the Catalent acquisition. 
    Via Benzinga
    Roche Retains Outlook After Two Out Of Three Big Hitters Top Sales Expectations
    The Swiss drugmaker kept its outlook for the year despite a third-quarter sales miss. 
    Via Investor's Business Daily
    Can Roche Challenge Lilly and Novo in the Weight Loss Market?
    One Wall Street analysts recently singled out a drug from pharma company Roche as a threat to Eli Lilly's oral GLP-1 candidate. 
    Via MarketBeat
    Genentech’s Vabysmo Improved Vision in Underrepresented Populations With Diabetic Macular Edema (DME) in a First-Of-Its-Kind Study
    From Genentech
    Via Business Wire
    Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up
    The company is working on treatments for forms of muscular dystrophy, and is taking on some of the biggest names in pharma. 
    Via Investor's Business Daily
    Jazz Pharmaceuticals' Zepzelca/Tecentriq Combo Regimen Can Potentially Delay Disease Progression, Extend Survival In Aggressive Form Of Lung Cancer
    Jazz Pharmaceuticals released Phase 3 trial results for Zepzelca in combination with Roche's atezolizumab as a maintenance treatment for extensive-stage small-cell lung cancer. Jazz plans to submit a... 
    Via Benzinga
    Why Amgen's Obesity Drug — And $5 Billion Opportunity — Led To A Downgrade
    The analyst is closely watching MariTide, a potential monthly injection to treat obesity. 
    Via Investor's Business Daily
    Majority of Children With Spinal Muscular Atrophy (SMA) Treated With Genentech’s Evrysdi Are Able to Sit, Stand and Walk Independently, Two-Year Data Demonstrate
    From Genentech
    Via Business Wire
    Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The Names
    The $200B GLP-1 market is set to expand with 16 new obesity drugs launching by 2029, challenging Novo Nordisk and Eli Lilly's dominance while addressing scalability and pricing concerns. 
    Via Benzinga
    FDA Approves Genentech’s Itovebi, a Targeted Treatment for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation
    From Genentech
    Via Business Wire
    Why Is Cancer Focused Tempest Therapeutics Stock Trading Higher On Thursday?
    Tempest Therapeutics enters a Phase 3 trial for its liver cancer drug amezalpat, in collaboration with Roche. The trial follows positive data from a Phase 2 study showing improved survival in patients... 
    Via Benzinga
    Nano-Cap Bio-Path Takes Plunge In Weight Loss Race, Initiates Obesity Program With Drug Candidate Under Development For Blood Cancer
    Bio-Path is advancing its obesity treatment BP1001-A and completing trials for BP1002 in acute myeloid leukemia, targeting resistance mechanisms in treatment. Preclinical studies for obesity are set... 
    Via Benzinga
    Scholar Rock's Muscle Wasting Drug Excels In Pivotal Trial, Plans FDA Submission Next Year
    Scholar Rock's Phase 3 SAPPHIRE trial for apitegromab in spinal muscular atrophy met its primary endpoint, showing statistically significant motor function improvements and favorable outcomes compared... 
    Via Benzinga
    Exposures Product Safety
    2 Artificial Intelligence Stocks That Could Deliver Explosive Gains
    These two AI innovators are reshaping drug discovery and voice technology – find out why Wall Street sees major upside ahead. 
    Via The Motley Fool
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    Economist Justin Wolfers Points To Obesity Rate Decline As Ozempic And Wegovy Spur Historic Shift In Fight Against Obesity — Has US Reached A Turning Point?
    Renowned economist Justin Wolfers highlighted this significant shift on social media platform X, stating, "From the Department of Things Really Are Getting Better: The U.S. obesity rate may have... 
    Via Benzinga
    Week In Review: Regor Sells Two CDK Inhibitors To Genentech For $850 Million
    Regor Pharma, a Shanghai-Boston biotech, sold global rights to Genentech for two early-stage CDK inhibitors aimed at breast cancer. Regor will receive $850 million upfront, a hefty amount for two Phase... 
    Via Talk Markets
    As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer
    Viking Therapeutics is an upstart in the weight-loss drugs space. But it's catching attention. 
    Via Investor's Business Daily
    3 Top Stocks That Could Still Rocket Higher in 2024
    Upcoming Food and Drug Administration decisions could push these stocks through the roof. 
    Via The Motley Fool
    Roche Fast-Tracks Obesity Drug Development, Eyes Over $3B Sales Potential
    Roche focuses on obesity drug development, fast-tracking its CT-388 candidate, and targeting $3.6 billion in annual sales. The company aims to launch 20 transformative drugs by 2030 while cutting... 
    Via Benzinga
    Positive Phase III Results for Genentech’s Gazyva Show Superiority to Standard Therapy Alone in People With Lupus Nephritis
    From Genentech
    Via Business Wire
    Netflix, Eli Lilly Lead 5 Fast Growers Near Buy Points
    NFLX is among four stocks on the list that's actionable now. 
    Via Investor's Business Daily
    Roche's Antiviral Drug Reduces Transmission Of Influenza Viruses, Late-Stage Study Shows
    Roche's phase 3 CENTERSTONE study shows Xofluza (baloxavir marboxil) significantly reduces influenza transmission in households, marking a global first for an antiviral. 
    Via Benzinga
    2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure?
    Pharma stock have been on the rise in the latter half of the year, but the 2024 election remains a wild card for shares. 
    Via Investor's Business Daily
    Positive Phase III Results Show Xofluza Significantly Reduces the Transmission of Influenza Viruses
    From Genentech
    Via Business Wire
    1 Telemedicine Stock I Wouldn't Touch With a 10-Foot Pole (Hint: It's Not Teladoc)
    Telemedicine once seemed like it was going to revolutionize healthcare. 
    Via The Motley Fool
    Back-To-Back FDA Approvals For Roche's Two Under-The-Skin Injections
    The FDA has approved Roche's Ocrevus Zunovo for relapsing and primary progressive multiple sclerosis, offering the first twice-a-year subcutaneous injection option for both forms of the disease. 
    Via Benzinga
    Exposures Product Safety
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    27 28 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.